Indexed in

License and use

Citations

Altmetrics

Analysis of institutional authors

Share

Acceptability of Long-Acting Injectable Antiretroviral Treatment for HIV Management: Perspectives of Patients and Physicians in Spain

Publicated to:AIDS PATIENT CARE AND STDS. 38 (7): 305-314 - 2024-07-01 38(7), DOI: 10.1089/apc.2024.0093

Authors: Moreno C; Izquierdo R; Alejos B; Hernando V; de la Cámara SP; Peraire J; Macías J; Bernal E; Albendín-Iglesias H; Alcaraz B; Suárez-García I; Moreno S; Jarrín I; Moreno S; Dalmau D; Navarro ML; González MI; Garcia F; Poveda E; Iribarren JA; Gutiérrez F; Rubio R; Vidal F; Berenguer J; González J; Muñoz-Fernández MÁ; Moreno C; Rava M; Izquierdo R; Marco C; Gómez-García T; Juárez R; Portilla J; Portilla I; Merino E; García G; Agea I; Sánchez-Payá J; Rodríguez JC; Giner L; Reus S; Boix V; Torrus D; Pérez V; Portilla J; Pinargote H; Alemán MR; Lirola AL; García D; Díaz-Flores F; Alonso MM; Pelazas R; Hernández MI; Romero L; Bethencourt A; Rodríguez D; Asensi V; Rivas-Carmenado ME; Magadan RC; Díaz-Arias J; Pulido F; Rubio R; Bisbal O; Hernando MA; Rial D; de Lagarde M; Pinto A; Bermejo L; Santacreu M; Navarro R; Torres JM; Iribarren JA; Aramburu MJ; Camino X; Goenaga MÁ; Bustinduy MJ; Azkune H; Ibarguren M; Kortajarena X; Álvarez-Rodriguez I; Gil L; Carmona-Torre F; Carlos AB; Sanz ML; Gutiérrez F; Robledano C; Masiá M; Padilla S; Adsuar A; Pascual R; Fernández M; Galiana A; García JA; Barber X; Abellán JG; Telenti G; Guillén L; Botella Á; Mascarell P; Carvajal M

Affiliations

Abstract

We assessed the prevalence and factors associated with HIV-infected patients’ interest in trying long-acting injectable antiretroviral treatment (LAI-ART) along with its expected benefits and concerns, and evaluated physicians’ opinions about LAI-ART. This study was set within the multi-center prospective CoRIS cohort, comprising HIV-positive adults, naïve to antiretroviral treatment (ART) at study entry, recruited from 2004 onward in 48 centers in Spain. In June 2022, we conducted a 2-day cross-sectional survey among patients across 34 CoRIS centers and sent an online questionnaire to all physicians prescribing ART in 39 CoRIS centers. Of the 271 patients included, 83.3% [95% confidence interval (CI)]: 78.0 - 87.0%) expressed interest in receiving LAI-ART. This interest was higher among men (adjusted odds ratio: 2.96; 95% CI: 1.4–6.12), those aged <50 years (2.41; 1.23 - 4.73), and individuals inconvenienced by oral ART (5.03; 1.47 - 17.15), daily intake (14.65; 3.44–62.46), carrying HIV pills constantly (7.19; 2.88 - 17.96), and taking multiple medications (3.94; 1.58 - 9.85). Among the 154 physicians surveyed, 45.5% believed LAI-ART would be the preferred option for patients. Although most physicians (92.9%) thought LAI-ART could improve patients’ quality of life (QoL), concerns were raised by 37.7% and 44.2% of them regarding injection site pain and visit rescheduling, respectively. Interest in LAI-ART was higher among men, those aged <50 years, and individuals finding their oral ART inconvenient. Physicians believed LAI-ART could improve QoL and overcome treatment challenges, yet concerns were raised about its potential usage difficulties. Although most patients were interested in receiving LAI-ART, only less than half of the physicians considered it their preferred option, likely owing to concerns about missed visits and injection site pain.

Keywords